NO20060019L - Fremgangsmater og preparater for interferonterapi - Google Patents

Fremgangsmater og preparater for interferonterapi

Info

Publication number
NO20060019L
NO20060019L NO20060019A NO20060019A NO20060019L NO 20060019 L NO20060019 L NO 20060019L NO 20060019 A NO20060019 A NO 20060019A NO 20060019 A NO20060019 A NO 20060019A NO 20060019 L NO20060019 L NO 20060019L
Authority
NO
Norway
Prior art keywords
interferon
protein
delivery
syn3
methods
Prior art date
Application number
NO20060019A
Other languages
English (en)
Norwegian (no)
Inventor
Tattanahalli L Nagabhushan
Heidrun Engler
Stephen Youngster
Robert Connor
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/455,215 external-priority patent/US20040014709A1/en
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO20060019L publication Critical patent/NO20060019L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20060019A 2003-06-04 2006-01-03 Fremgangsmater og preparater for interferonterapi NO20060019L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47592603P 2003-06-04 2003-06-04
US10/455,215 US20040014709A1 (en) 1996-01-08 2003-06-04 Methods and compositions for interferon therapy
PCT/US2004/017788 WO2004108088A2 (en) 2003-06-04 2004-06-04 Methods and compositions for interferon therapy

Publications (1)

Publication Number Publication Date
NO20060019L true NO20060019L (no) 2006-03-03

Family

ID=33513856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060019A NO20060019L (no) 2003-06-04 2006-01-03 Fremgangsmater og preparater for interferonterapi

Country Status (9)

Country Link
US (1) US20050025742A1 (https=)
EP (2) EP1629085A2 (https=)
JP (3) JP2007526219A (https=)
KR (1) KR20060012661A (https=)
AU (2) AU2004245995A1 (https=)
BR (1) BRPI0410915A (https=)
CA (2) CA2528136A1 (https=)
NO (1) NO20060019L (https=)
WO (1) WO2004108088A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
ES2745068T3 (es) * 2001-12-20 2020-02-27 Merck Sharp & Dohme Composiciones de SYN3 y métodos
US20030198624A1 (en) * 2002-03-02 2003-10-23 Mohapatra Shyam S. Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer
CA2484251C (en) 2002-04-30 2015-06-23 University Of South Florida Materials and methods for inhibition of respiratory syncytial virus infection
US7595303B1 (en) * 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
WO2004074314A2 (en) * 2003-02-14 2004-09-02 University Of South Florida Chistosan-microparticles for ifn gene delivery
US7355056B2 (en) * 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
CA2548100C (en) * 2003-12-10 2015-03-24 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
WO2005105136A1 (en) * 2004-04-27 2005-11-10 University Of South Florida Nanogene therapy for cell proliferation disorders
TWI305230B (en) * 2004-06-25 2009-01-11 Univ Feng Chia Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein
CA2590943C (en) 2004-12-13 2013-10-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
EP3442588A4 (en) 2016-04-14 2020-02-19 Trizell Ltd. STABILIZING VIRUS VECTORS
AU2021237818A1 (en) * 2020-03-19 2022-09-29 Ferring Ventures Ltd. Temperature-responsive virus storage system
WO2026077967A1 (en) * 2024-10-08 2026-04-16 Ferring International Center Sa Method for making syn3

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5298222A (en) * 1989-08-09 1994-03-29 Osteotech, Inc. Process for disinfecting musculoskeletal tissue and tissues prepared thereby
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5118512A (en) * 1990-01-23 1992-06-02 Osteotech, Inc. (A Delaware Corp.) Process for cryopreserving biological materials and materials prepared thereby
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy

Also Published As

Publication number Publication date
BRPI0410915A (pt) 2006-06-27
AU2004245074A1 (en) 2004-12-16
WO2004108088A2 (en) 2004-12-16
EP1628624A2 (en) 2006-03-01
CA2527658A1 (en) 2004-12-16
EP1629085A2 (en) 2006-03-01
WO2004108088A3 (en) 2006-04-20
JP2007269808A (ja) 2007-10-18
JP2006526661A (ja) 2006-11-24
KR20060012661A (ko) 2006-02-08
CA2528136A1 (en) 2004-12-16
AU2004245995A1 (en) 2004-12-16
US20050025742A1 (en) 2005-02-03
JP2007526219A (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
NO20060019L (no) Fremgangsmater og preparater for interferonterapi
US10888627B2 (en) Nucleic acid products and methods of administration thereof
Pezzulo et al. HSP90 inhibitor geldanamycin reverts IL-13–and IL-17–induced airway goblet cell metaplasia
EP3543339A1 (en) Nucleic acid products and methods of administration thereof
Dash et al. An injectable elastin-based gene delivery platform for dose-dependent modulation of angiogenesis and inflammation for critical limb ischemia
Scharffetter et al. Synergistic effect of tumor necrosis factor-α and interferon-γ on collagen synthesis of human skin fibroblasts in vitro
Tian et al. Myocardin-related transcription factor A (MRTF-A) plays an essential role in hepatic stellate cell activation by epigenetically modulating TGF-β signaling
Sugahara et al. Alveolar epithelial cells: differentiation and lung injury
JP2004530401A (ja) 細胞への核酸の送達を促進する方法および成分
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
Sidhu et al. Melatonin treatment is beneficial in pancreatic repair process after experimental acute pancreatitis
JP6073238B2 (ja) 皮膚細胞分化促進物質のスクリーニング方法
Song et al. Irisin reverses platelet derived growth factor-BB-induced vascular smooth muscle cells phenotype modulation through STAT3 signaling pathway
Guo et al. Potential role of MG53 in the regulation of transforming-growth-factor-β1-induced atrial fibrosis and vulnerability to atrial fibrillation
MX2023007609A (es) Métodos para mejorar la terapia génica no viral.
Benitez et al. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic‐and cholestatic‐induced liver injury
De Berdt et al. The human dental apical papilla promotes spinal cord repair through a paracrine mechanism
Schultheiss Regenerative medicine in andrology: Tissue engineering and gene therapy as potential treatment options for penile deformations and erectile dysfunction
WO2024012435A9 (en) Gene editing systems and methods for treating hereditary angioedema
WO2004019761A3 (en) Methods of treating age-related defects and diseases
CN110404074A (zh) Ogdh抑制物在治疗病毒感染性疾病中的应用
Melman et al. Gene therapy in the management of erectile dysfunction (ED): past, present, and future
Shin et al. Fibroblast growth factor 7 (FGF7) as a key mediator in the pathological changes of whole joint tissues in Osteoarthritis
CN107050045A (zh) 裸鼹鼠巨型分子量透明质酸在制备治疗乳腺癌药物中的应用
JP2026504432A (ja) 哺乳動物における医療用途のための組織メタロプロテアーゼ阻害物質タンパク質をコードするオリゴヌクレオチド

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application